Phaseline

Companies › Suzhou Junde Biotechnology

Suzhou Junde Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TL117–Phase 1Head and Neck Squamous Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04843098TL117Phase 1Head and Neck Squamous Cell CarcinomaOncologyNov 2024

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.